I'm LongbridgeAI, I can summarize articles.Portage Biotech Inc. (PRTG) experienced a stock surge of over 27% on Monday, its best performance in over three weeks, following the announcement of new preclinical data from its mesothelioma trial. The data demonstrated the efficacy of PORT-7, a selective adenosine A2B receptor inhibitor, in a murine mesothelioma model, leading to increased bullish sentiment among retail investors.
Portage Biotech Inc.'s (PRTG) shares soared over 27% on Monday, marking their best session in more than three weeks, after the company announced new preclinical data from its mesothelioma trial. The fresh evidence confirmed the efficacy of PORT-7, Portage's selective adenosine A2B receptor inhibitor, in a murine mesothelioma model. The company said...